{
    "clinical_study": {
        "@rank": "122789", 
        "acronym": "PRESIDEX", 
        "arm_group": [
            {
                "arm_group_label": "Dexamethasone", 
                "arm_group_type": "Active Comparator", 
                "description": "Dexamethasone 12 mg, 2 doses, 12 hours apart."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo, 2 doses, 12 hours apart"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a double blinded, placebo-controlled trial to determine if IV dexamethasone more\n      quickly than placebo assists resolution of Posterior Reversible Encephalopathy Syndrome\n      (PRES) encountered in eclamptic patients.  All patients regardless of assignment to placebo\n      or steroid will receive standard therapy to include magnesium sulfate, blood pressure\n      medications and diuretics.  We hypothesize that the addition of dexamethasone to standard\n      therapy will accelerate CNS recovery more quickly than standard management without\n      dexamethasone."
        }, 
        "brief_title": "Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Eclampsia", 
        "condition_browse": {
            "mesh_term": [
                "Eclampsia", 
                "Posterior Leukoencephalopathy Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "30 eclamptic patients who do not require steroids for fetal lung maturation purposes will be\n      randomized to placebo or steroid.  This includes patients with eclampsia encountered\n      antepartum prior to 23 weeks gestation, postpartum eclampsia, undelivered patients\n      encountered after 33 weeks gestation who would not be candidates for fetal lung maturation\n      steroids, or patients not eligible for repeat steroid administration in the 23-34 week\n      gestational window.  Planned enrollment in this pilot study is up to 30 patients with at\n      least 12 in each group."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Currently 34 weeks pregnant or within 6 weeks postpartum\n\n          2. At least 18 years of age\n\n          3. Singleton or twin gestation\n\n          4. Patient or family sign informed consent\n\n          5. Diagnosis of eclampsia\n\n          6. Able to obtain MRI scanning within 24hours of hosp admit and/or seizure\n\n        Exclusion Criteria:\n\n          1. Neither pregnant nor within first 6 weeks postpartum\n\n          2. Patient or family unable to sign informed consent\n\n          3. Less than 18 years of age\n\n          4. Triplet or higher order gestation\n\n          5. Unable to obtain MRI scanning within 24 hours of hospital admission (\n\n          6. Diagnosis of cerebral hemorrhage\n\n          7. Patient in whom MRI is contraindicated"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02027272", 
            "org_study_id": "2011-0269"
        }, 
        "intervention": {
            "arm_group_label": "Dexamethasone", 
            "description": "Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart", 
            "intervention_name": "Dexamethasone", 
            "intervention_type": "Drug", 
            "other_name": "Potent glucocorticoid or steroid"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Glucocorticoids", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Eclampsia", 
        "lastchanged_date": "January 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Jackson", 
                    "country": "United States", 
                    "state": "Mississippi", 
                    "zip": "39216"
                }, 
                "name": "University of Mississippi Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES): A Randomized Clinical Trial Evaluating Corticosteroid Efficacy to Augment Standard Therapy and Shorten Recovery.", 
        "overall_official": {
            "affiliation": "University of Mississippi Medican Center", 
            "last_name": "James Martin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To learn if giving IV dexamethasone to eclamptic women with PRES will accelerate normalization of CNS function.", 
            "measure": "Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES): Arandomized clinical trial evaluating corticosteroid efficacy to augment standard therapy and shorten recovery", 
            "safety_issue": "No", 
            "time_frame": "36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02027272"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Mississippi Medical Center", 
            "investigator_full_name": "James Martin", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Mississippi Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Mississippi Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014", 
        "why_stopped": "Difficulty recruiting, only one participant in 18 months, rarity of event"
    }
}